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A B S T R A C T
Purpose: The purpose of the current review is to highlight, on one hand, the fact that the migratory pattern of
glioma cells is the major obstacle to combat them with chemotherapy, and on the other one, the new treatment
strategies to overcome this obstacle.
Methods: This review surveys several membrane and extracellular molecules involved in glioma cell migration,
invasiveness and resistance to apoptosis.
Results: This review focuses on signaling pathways implicated in the positive regulation of glioblastoma cell
migration, including glutamate and ion channel networks, microtubes and membrane-derived extracellular
vesicles (EV) containing microRNAs. Glioma cells release glutamate to the extracellular matrix, inducing neu-
ronal cell death, which may facilitate glioma growth and invasion. Glioma cell migration and invasion are
further facilitated through ion channels and transporters that modify cellular volume. Microtubes and EV pro-
mote connections and communication among glioma cells and with the microenvironment and are associated
with progression and resistance to therapy. Potential therapies linked to these pathways for glioblastoma are
being developed.
Conclusion: Our view is evolving from an intracellular view of the complex intracellular signaling pathways to
one of orchestral machinery, including connections between heterogeneous tumoral and nontumoral cells and
with the microenvironment through channels, microtubes, and extracellular miRNA, generating diﬀerent signals
at diﬀerent times. All of these elements give rise to a new perspective for the treatment of glioblastoma.
Introduction
Gliomas, including the most common variant, glioblastoma, are the
most common primary malignant brain tumors, with an annual in-
cidence of 5.26 cases per 100,000 population or 17,000 new diagnoses
per year [1]. Glioblastoma remains one of the most lethal forms of
cancer. The high spatial and temporal glioblastoma heterogeneity due
to functionally diverse cell types, chaotic leaky vasculature and tumor
cell inﬁltration contributes to poor prognosis in patients [2]. The cur-
rent understanding of the biology and genetics of glioblastoma has
greatly improved in the past two decades. Two major multi-institutional
programs, the Glioma Molecular Diagnostic Initiative and The Cancer
Genome Atlas (TCGA), have pursued comprehensive genomic char-
acterization of a large number of clinical glioma samples using a variety
of technologies to measure gene expression, chromosomal copy number
alterations, somatic and germline mutations, DNA methylation, mi-
croRNA, and proteomic changes. These data will facilitate the discovery
of therapeutic and diagnostic targets and pathway candidates, valida-
tion of research and clinical observations and generation of un-
anticipated hypotheses that can advance the molecular understanding
of this lethal cancer [3]. Sturm et al. identiﬁed six epigenetic glio-
blastoma subgroups displaying characteristic global DNA methylation
patterns, harboring distinct hotspot mutations, DNA copy-number al-
terations, and transcriptomic patterns [4]. Brenann et al. provided a
comprehensive and in-depth overview of the genetic, epigenetic and
transcriptional proﬁles associated with glioblastoma [5]. The new WHO
2016 classiﬁcation, therefore, is not only based on the histological
features of the tumor but also includes isocitrate dehydrogenase (IDH)
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mutation and chromosomal arms 1p and 19q codeletion status to
classify diﬀuse gliomas of adulthood [6]. However, each individual
glioblastoma should be considered as an ensemble of molecularly dis-
tinct subclones that reﬂect a spectrum of dynamic cell states. It is be-
coming clear that glioblastoma is a composite of multiple cell popula-
tions in the same tumor, and this heterogeneity makes the design of
eﬀective treatment modalities challenging [7,8].
Diﬀuse glioma genesis
In the context of gliomagenesis, glial cells were once considered the
only dividing cells in the postnatal brain, making these cells the only
brain cells susceptible to transformation [9,10]. It is now known that
both multipotent and self-renewing neural stem cells and self-renewing
glial progenitor cells produce astrocytes and oligodendrocytes in lim-
ited regions of the adult brain including the subventricular zone, the
subgranular zone of the dentate gyrus and possibly other minor stem-
cell niches throughout the brain [11–13]. These stem cell and pro-
genitor elements, in addition to diﬀerentiating into adult glia, are now
thought to constitute a substrate for neoplastic transformation, termed
glioma initiating cells or glioma stem cells (GSCs), a small population of
self-renewal, therapy-resistant and slow-dividing malignant cells inside
the main tumor bulk. Calabrese et al. found that a signiﬁcant propor-
tion of vessel-associated Nestin+ tumor cells are proliferating and that
these cells are distributed throughout tumors, from all regions of the
cerebrum and cerebellum [14]. In the early 70 s, Pierce proposed that
tumors arise from carcinogenic events occurring in stem cells of a
particular tissue that cause a defect in the control of normal stem cell
function, including self-renewal and diﬀerentiation [15]. In the adult
brain, neural stem cells commonly possess features associated with
gliomas, including a robust proliferative potential, high motility, di-
verse progeny, associations with blood vessels and white-matter tracts
and an immature gene expression proﬁle characterized by expression of
nestin, epidermal growth factor receptor (EGFR), Notch and PTEN,
telomerase activity, and Hedgehog and Wnt pathway activities
[16–19].
GSCs expresse nestin (an intermediate ﬁlament protein) and CD133
(also known as prominin 1, a transmembrane glycoprotein), factors
associated with neural stem cells, although some GSCs are CD133-ne-
gative [20]. Although CD133 expression seems to be related to stem-
ness, it might only indicate an intermediate, adaptive state of a cell
rather than a stable phenotype [21]. A tumor is therefore a caricature of
normal tissue and appears to be undiﬀerentiated because of the pre-
ponderance of undiﬀerentiated proliferating stem cells in relationship
to the number of cells that have diﬀerentiated and are post-mitotic.
Stem and progenitor cells in the central nervous system may be
particularly at risk for malignant transformation since they con-
stitutively activate the cellular machinery necessary for tumor initia-
tion, progression or both (including growth factor receptor EGFR, PI3K,
Akt, mTOR, Ras, mitogen-activated protein kinase (MAPK) members).
Thus, neural stem cells may represent the path of least resistance in
tumorigenesis since these cells already have the ability to bypass
apoptosis and senescence. As a result, neural stem cells may require less
than the estimated four to seven mutations needed to induce malignant
change in a diﬀerentiated cell [22]. In gliomas, as in several solid tu-
mors outside the central nervous system, only a small fraction of the
total population of cancer cells are clonogenic cancerous neural stem
cells. However, this resistant population is considered the primary
cause of glioblastoma invasion and responsible for the maintenance of a
minimal residual disease, which commonly leads to post-therapeutic
recurrence [23]. Evidence from human gliomas and rodent glioma
models indicate that the glioma vascular niche supports glioma stem
cell maintenance and nurtures tumor growth by oﬀering nutrients ne-
cessary for unlimited glioma stem cell proliferation [14,24]. Several
embryonic signaling pathways, such as Notch, Hedgehog and Wnt/b-
catenin, have been reported to help maintain the GSC pool and thus
provide potentials target for treating glioblastoma [25]. Paw et al. [26]
and Lee et al. [27] recently provided an overview of the speciﬁc sig-
naling pathways that regulate glioblastoma stem cell maintenance and
migration.
On the basis of their histological appearance, gliomas have been
traditionally classiﬁed as astrocytic, oligodendroglial or ependymal
tumors and assigned WHO grades I-IV, which indicate diﬀerent degrees
of malignancy. Diﬀusely inﬁltrating gliomas in adults are now sepa-
rated into three overarching tumor groups with distinct natural his-
tories, responses to treatment and outcomes: IDH-mutant, 1p/19q co-
deleted tumors with mostly oligodendroglial morphology that are as-
sociated with the best prognosis; IDH-mutant, 1p/19q non-co-deleted
tumors with mostly astrocytic histology that are associated with inter-
mediate outcome; and IDH wild-type, mostly higher WHO grade (III or
IV) tumors that are associated with poor prognosis [28].
Treatment
The current standard treatment for glioblastoma includes surgical
resection, followed by radiotherapy plus concomitant temozolomide
(TMZ) followed by six cycles of maintenance TMZ [29,30]. These
treatments allow a median overall survival in the range of 16months in
clinical trial patient populations, but are never curative. Indeed, less
than 10% of the 77,000 patients diagnosed each year with glioblastoma
in the USA and Europe will survive more than 5 years. This dismal
prognosis reﬂects the high rate of tumor recurrence approaching 100%
which is linked to the profoundly inﬁltrative nature of this tumor,
rendering curative surgical resection elusive, and its relative resistance
not only to the conventional treatments of genotoxic radiotherapy and
chemotherapy, but also more recently to targeted therapies. Anti-
angiogenic therapies have dominated the clinical trial landscape of
glioblastoma. However, it has now become clear that this approach is
hopeless, at least with a view to prolonging overall survival. Indeed,
while anti-angiogenic treatment targeting VEGF exerts anti-edema ef-
fects in glioblastoma which may translate into clinical beneﬁt in sub-
groups of patients, no clinical trial has demonstrated a survival beneﬁt
aﬀorded by anti-angiogenic agents.
Glioblastoma migration: What is new?
In a previous review we highlighted the complex dynamic processes
governing glioma cell migration in general and in glioblastoma in
particular [31]. This dynamic process includes, among others, (i) cell
adhesion to numerous components of a modiﬁed (when compared to
normal parenchyma) extracellular matrix (ECM); (ii) cell motility,
which involves the reorganization of the actin cytoskeleton, primarily
through modiﬁcations in the ﬁeld of integrin network–ECM component
interactions; and (iii) invasion, which involves the degradation of ma-
trix proteins by tumor-secreted proteolytic enzymes, primarily serine
proteases, cathepsins and metalloproteinases (MMPs). Admittedly, no
eﬀective treatments for human glioma patients have evolved from these
avenues of research.
In the present review, we analyzed the recent literature on new
promising therapies to combat glioblastoma with a focus on two pa-
thognomonic features of glioblastoma biology, i.e., glioblastoma cell
migration and invasion through the brain parenchyma and, associated
with that, the apparent intrinsic resistance of migrating glioblastoma
cells to pro-apoptotic stimuli, including cytotoxic chemotherapy and
radiotherapy.
We focused in the current review on glutamate, ion channels, tumor
microtubules and several signaling pathways. While there is a myriad of
signaling pathways that inﬂuence the migratory behavior of malignant
astrocytes [31], we decided to restrain ourselves on the “glutamate
pathway” because we are convinced that impairing this malignant as-
trocyte-migration avenue of invasion within the brain parenchyma
would actually contribute therapeutic beneﬁts to the patients. We detail
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below why we believe in this avenue to combat malignant gliomas.
Interaction of glutamate, glutamate transporters and glutamate receptors
The release of the neurotransmitter glutamate from glioma cells has
been well studied in vitro and in vivo as well as in glioblastoma patient
populations [32–34]. The Na+-independent, Cl--dependent, cystine/
glutamate exchanger system (SXC) is the only transporter identiﬁed in
glioma cells that has the ability to release large amounts of glutamate
[32]. Glutamate released from malignant glioma cells into the extra-
cellular space has been linked to seizure induction, and at higher con-
centration, glutamate is thought to induce neuronal cell death, medi-
ated mainly by prolonged activation of N-methyl-D-aspartate (NMDA)
receptors, but also via α-amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionic acid (AMPA) and kainate receptors resulting in Ca2+ inﬂux and
Ca2+-mediated cell death (Fig. 1) [35–37]. In the healthy brain, ex-
citatory amino acid transporters (EAAT), located on astrocytes (EAAT1
and-2) and neurons (EAAT2), are responsible for the majority of glu-
tamate uptake, and astrocytes can rapidly reduce toxic concentrations
of extracellular glutamate. Glioma cells lack EAAT-mediated glutamate
transport which contributes to the elevated peritumoral levels observed
in glioma patients and in animal models of glioma [38]. Moreover,
Robert and Sontheimer hypothesized that glioma cells alter peritumoral
astrocyte EAAT function, preventing the re-establishment of glutamate
homeostasis, as typically occurs in the healthy brain [38]. Investiga-
tions eﬀectively discovered that glioma cells lack EAAT2-mediated
glutamate transport [39]. These ﬁndings were corroborated by micro-
array analyses of human glioma biopsies demonstrating the absence of
EAAT2 expression in patient glioma tissue [39].
By contrast, glioma cells express NMDA, a-amino-3-hydroxy-5-me-
thyl-4-isoxaole propionic acid (AMPA) and metabotropic (mGlu) re-
ceptors [40]. However, van Vuurden et al. showed that on protein level,
AMPA-type glutamate receptor subunits are variably expressed in
glioblastoma and are overall down-regulated as compared to the
normal brain tissue [41]. These authors further reported that down-
regulation of AMPA receptor expression and mislocalization of these
receptors enables the cells to survive in a high glutamate environment
without undergoing excitotoxic cell death themselves [41].
Glutamate stimulates the growth, migration and invasion of neu-
roglial tumor cells through activation of Ca2+-permeable glutamate
AMPA receptors on glioma cells in a paracrine and autocrine manner
(Fig. 1). AMPA receptor expression correlates with an increase in sur-
face expression of β1 integrin, a molecule implicated in glioma inva-
sion, and AMPA receptor stimulation increases glioma cell de-adhesion
from surrounding cells. Glial AMPA receptors activate focal adhesion
kinase (FAK) which inﬂuences cytoskeletal rearrangement and focal
adhesion contact formation [42].
Additionally, in response to reactive oxygen species (ROS), glioma
cells upregulate SXC activity to provide intracellular cysteine for en-
hanced glutathione (GSH) synthesis, an important intracellular anti-
oxidant that promotes cell survival [43]. Increased GSH neutralizes
ROS, preventing cell destruction triggered by hypoxia; inhibits apop-
tosis signaling, protecting cells from degradation; and via ROS antag-
onism, may play an important role in the development of resistance to
radiotherapy and chemotherapy [44].
Roles of ion channels, transporters and exchangers
Increasing evidence suggests that cellular migration and invasion in
cancer cells in general and glioma cells in particular results from shape
and volume changes facilitated by ion channels and transporters
[45–48]. Glioma cells principally use voltage-gated chloride and po-
tassium channels as well as the KCa family of Ca2+-activated potassium
channels ([47] for a review of this topic) (Fig. 2).
Fig. 1. The glutamatergic system in glioblastoma. Glial tumor cells release glutamate by means of the Na+-independent, Cl--dependent, cystine/glutamate exchanger
system (SXC) transporter. Glutamate released from malignant glioma cells in the extracellular matrix is responsible for seizure induction and, at a higher con-
centration, neuronal cell death, which is mediated by prolonged activation of neuronal N-methyl-D-aspartate (NMDA) receptors, resulting in Ca2+ inﬂux and Ca2+-
mediated cell death. This neuronal cell death may facilitate tumor growth. Glutamate also stimulates growth, migration and invasion of glial tumor cells through
activation of Ca2+-permeable glutamate AMPA receptors on glioma cells in a paracrine and autocrine manner.
F. Lefranc et al. Cancer Treatment Reviews 68 (2018) 145–154
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Potassium channels
Among ion transporters, potassium channels show the highest
variability and the most frequently altered pattern of expression in
many tumor types [49]. Cell cycle, proliferation, migration, invasion,
angiogenesis and apoptosis are all processes that can be modiﬁed by the
expression of potassium channels [50]. Potassium channels have been
implicated in every step of adhesion and migration [45]. Interactions of
potassium channels with crucial contributors to cell adhesion, such as
FAK and cortactin, an actin-interacting protein implicated in the cy-
toskeletal architecture and often ampliﬁed in several types of cancer,
have been reported (Fig. 2) [51]. Potassium channels also associate
with the main contributors to cell adhesion signaling, integrins. The
most important understood mechanisms by which particular potassium
channels contribute to cancer initiation and progression have recently
been reviewed [48]. Here we focus on the literature on potassium
channels involved in glioma progression and migration, e.g. Kv1.3 and
Kv1.5 [52–54], Kv10.1 [55–57], Kv11.1 [58], KCa1.1 [59,60] and
KCa3.1 [61] (Fig. 2).
The Kv1.3, Kv10.1, and Kv11.1 channels are the best studied vol-
tage-gated K channels in the context of cell migration. They are of
particular importance for cells of the immune system and tumor cells,
including glioblastoma cells, constituting potential diagnostic or prog-
nostic markers or even therapeutic targets [48,50].
Kv10.1 (also known as EAG1, ether-à-go-go and KCNH1), a voltage-
gated potassium channel that is virtually absent from normal cells
outside the central nervous system, is expressed in limited areas of the
brain (hypothalamus, hippocampus, cerebral cortex, cerebellum and
olfactory nerve) but highly expressed in diﬀerent cancers, including
brain metastases and gliomas [57]. Bai et al. also observed Kv10.1
overexpression in both glioma cell lines and clinical glioma samples
[55]. In several diﬀerent cancers, Kv10.1 enhances proliferation. It has
also been shown to be required for the maintenance of growth asso-
ciated with the p53/miRNA34/E2F1 regulatory pathway in SHSY5Y
human dopaminergic neuroblastoma cells [62]; this channel up-reg-
ulates HIF-1 and VEGF in the tumor environment [63] and increases
migration [64]. Kv10.1 expression in Chinese Hamster Ovary (CHO)
cells aﬀects cytoskeletal organization, which might inﬂuence cancer
cell proliferation, migration and metastasis [64].
A correlation between dismal prognosis and Kv10.1 expression in
patients with brain metastasis from diﬀerent carcinomas has been ob-
served, and metastatic cancer patients receiving tricyclic anti-
depressants (such as imipramine, chlorimipramine, citalopram and
amitriptyline) showed a signiﬁcantly longer median overall survival
than patients not treated with these agents [57].
Kv11.1 (also known as HERG or KCNH2) was among the ﬁrst vol-
tage-gated channels directly associated with cancer [65]. Further,
Kv11.1 blockers impair the proliferation of tumor cells [66]. Kv11.1
physically interacts with β1 integrin at the plasma membrane of human
cancer cells to regulate survival and migration [67] (Fig. 2), and this
channel has also been implicated in the regulation of apoptosis of
human glioblastoma cells (see below) [68].
The Kv1.3 and Kv1.5 channels modulate Ca2+ signaling and cell
volume and have been analyzed in a number of cancer cell types [69].
The levels of expression of the Kv1.5 and Kv1.3 channel subtypes vary
between diﬀerent glioma groups, and diﬀerential expression of Kv1.5
according to malignancy grade has been noted [52]. Kv1.5 also con-
tributes to the resistance to pro-apoptotic stimuli of cancer cells, in-
cluding gliomas (see below).
The calcium-activated potassium channels KCa1.1 and KCa3.1 are
important for the migration of glioma and glioma stem cells [61,70,71].
The REepository of Molecular BRAin Neoplasia DaTa (REMBRANDT)
database allowed to determine that the gene KCNN4, which encodes
KCa3.1, is overexpressed in 32% of gliomas, and that its expression
correlated with short survival [70]. Turner et al. generated U251
glioma cells that stably express an inducible knockdown shRNA to ex-
perimentally eliminate KCa3.1 expression [70]. Subjecting these cells to
a combination of in vitro and in situ invasion assays revealed that KCa3.1
expression may enhance glioma invasion and either speciﬁc pharma-
cological inhibition with TRAM-34 or elimination of this channel by
gene silencing impairs invasion. Importantly, after intracranial im-
plantation into SCID mice, ablation of KCa3.1 with inducible shRNA
from U251 cells resulted in a signiﬁcant reduction in tumor invasion
into the surrounding brain [70].
Migration of glioblastoma cells can be stimulated by ionizing ra-
diation (IR) [72]. Steinle et al. accordingly analyzed the IR-induced
increase in Ca2+-activated potassium channel activity and its eﬀect on
Fig. 2. Glioma cell volume and shape reg-
ulation: involvement of ion channels. Cell
migration and glioblastoma cell migration
in particular is characterized by the polar-
ized cellular and molecular processes that
promote the protrusion of the leading edge
(local volume increase) and retraction of
the trailing edge (local volume reduction).
A net outﬂow of ions and water at the cell
trailing edge and a net inﬂow of ions and
water at the cell leading edge underlie these
localized hydrodynamic changes. Ion chan-
nels and transporters display polarized
subcellular distribution. At the trailing
edge, calcium entry through calcium-
permeable channels can activate calcium-
activated potassium channels (KCa) to pro-
mote potassium eﬄux. The opening of
chloride (KCl) and potassium channels (Kv)
further enhances the outﬂow of ions Cl- and
K+, followed by obligatory water eﬄux
through aquaporins. At the leading edge, an
assortment of inward ion channels, such as
the Na+/K+ ATPase and the Na+-K+-Cl-
cotransporters (NKCC1) together with
aquaporins, regulate ion and water inﬂux.
This ion and water inﬂux drives local cell
volume increase in the protruding lamelli-
podium for leading edge extension.
F. Lefranc et al. Cancer Treatment Reviews 68 (2018) 145–154
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the migration of T98G and U87MG cells [73]. IR dose-dependently
stimulated migration of glioblastoma cells, which in turn was sensitive
to the channel inhibitor paxilline. These authors concluded that IR
stimulates potassium channel activity, resulting in the activation of
Ca2+/calmodulin-dependent protein kinase II and enhanced glio-
blastoma cell migration [73].
Chloride channels
Approximately 20 years ago, Sontheimer proposed that the invasive
migration of human glioma cells into the normal brain parenchyma
requires shape and/or volume changes [74]. Chloride currents may
contribute to such shape-volume changes by aﬀecting net salt ﬂuxes
across glioma cell membranes, with accompanying water eﬄux, re-
sulting in cell shrinkage that is conducive to glioma cell migration
through minute extracellular spaces of the brain [75]. Sontheimer and
collaborators subsequently performed a direct examination of Cl- dy-
namics in human glioma cells and its functional relationship to cell
biology [76]. First, these authors observed that invasive tumor cells
become morphologically polarized and develop membrane protrusions
(Fig. 2). During this process, invasive glioma cells alter their cell shape
and volume to ﬁt into the narrow extracellular spaces available and
invade the brain parenchyma. These features include secretion of Cl-
and K+ through ion channels localized to lipid raft domains on in-
vadopodia and water passively ﬂowing through water channels or
aquaporins [46]. In addition, the interplay between Na+-K+-Cl- co-
transporters and Na+/K+ ATPase leads to active accumulation of K+
and Cl-, establishing a gradient for KCl eﬄux (Fig. 2) [46].
Here, we do not review the roles of other channels involved in
glioma migration, such as transient receptor potential (TRP) calcium
channels, which also contribute to changes in Ca2+ by modulating the
driving force for Ca2+ entry as Morrone et al. recently summarized this
subject [77].
Microtubes
Osswald et al. reported that astrocytomas but not oligoden-
drogliomas develop functional multicellular network structures through
ultra-long membrane protrusions and that astrocytoma cells use these
distinct tumor microtubes as routes for brain invasion, proliferation,
and interconnections over long distances [78]. The resulting network
facilitates multicellular communication through microtube-associated
gap junctions. Confocal microscopy revealed punctate connexin 43
(Cx43) gap junction immunoreactivity, particularly at the tumor mi-
crotubes of astrocytoma cells, which was not observed for other con-
nexins. When damage to the network occurs, tumor microtube is used
for repair. Moreover, microtube-connected astrocytoma cells, but not
those remaining unconnected throughout tumor progression, were
protected from cell death inﬂicted by radiotherapy. Osswald et al. hy-
pothesized that intercellular tumor microtubes can serve as an in-
dividual tumor cell to distribute critical elevations of small molecules,
such as calcium, within the large network (Fig. 3), achieving nonlethal
levels for radiotherapy-induced cytotoxicity and for intrinsic apoptotic
cell death in glioma cells [78]. Neuronal growth-associated protein 43
(GAP-43) is important for microtube formation and function and drives
microtube dependent tumor cell invasion, proliferation, interconnec-
tion, and radioresistance. The disconnection of astrocytoma networks
by disrupting their tumor microtubes may emerge as a new principle to
reduce the treatment resistance of this disease, but clinical applications
have not been introduced [78].
Extracellular MicroRNAs
Over the past decade, there has been increased awareness of the
possible role of microRNAs (miRNAs) in the development of cancer,
including glioblastoma [79]. miRNAs are small non-coding RNAs of
approximately 20–23 nucleotides that act as post-transcriptional
regulators of gene expression. miRNAs repress gene expression by
binding to complementary sequences in the 3′ untranslated region (3′
UTR) of mRNAs and targeting these molecules for degradation, thereby
preventing their translation, resulting in a decreased level of encoded
proteins that aﬀect an array of cellular processes, e.g., diﬀerentiation,
proliferation, migration, metabolism, apoptosis and stem cell main-
tenance [80]. Aberrant miRNA biogenesis in cancer occurs at diﬀerent
steps during miRNA maturation [79], and a single miRNA can regulate
the expression of many genes. Depending on its target genes, miRNA
can act as a tumor suppressor or tumor promoter. The accumulation of
speciﬁc miRNAs in glioblastoma samples from patients and in glio-
blastoma cell lines was initially demonstrated a decade ago [81,82].
Since then, numerous reviews have highlighted the involvement of
miRNAs in glioblastoma progression, migration and radio-che-
motherapy resistance and suggested their potential as therapeutic tar-
gets [83–89].
Recently, microRNAs have also been localized to the extracellular
space, often encapsulated in secreted extracellular vesicles (EV), nan-
ometer size membrane-enclosed particles formed either from the fusion
of an endosome with the plasma membrane (exosomes) or directly from
the cell membrane (microvesicles) and released from numerous cell
types, including glioblastoma cells, to mold the tumor microenviron-
ment to their advantage (Fig. 3) [90–92]. Neighboring or distant re-
cipient normal and tumor cells can take up EVs containing tissue-spe-
ciﬁc expressed/secreted microRNAs [93]. In a recent review, Rooj et al.
discussed the current knowledge regarding the multifaceted roles of
both cellular and EV microRNAs in shaping the glioblastoma micro-
environment [92]. Glioblastoma EVs are enriched in several oncogenic
microRNAs, including miR-21, miR-23a, miR-30a, miR-221 and miR-
451 [94]. However, the functions of most of these microRNAs remain
unknown. Hoshino and colleagues elegantly demonstrated that tumor-
derived EVs are internalized in organ-speciﬁc cells, and this process
plays an important role in the preparation of the pre-metastatic niche
[95]. EVs containing miRNA were also detected in the blood or the
cerebrospinal ﬂuid of glioblastoma patients [96]. Thus, microRNAs
circulating in complexes with tumor-originated EVs represent a po-
tential source of biomarkers for the early detection and monitoring of
tumor responses to treatment and could be utilized for glioblastoma
therapy using therapeutic mi-RNA [93]. Arscott et al. showed that ir-
radiation increases the abundance of exosomes released by glio-
blastoma cell lines and normal astrocytes [97]. These authors showed
that exosomes derived from irradiated cells enhanced the migration of
recipient cells, and their molecular proﬁling revealed an abundance of
molecules related to signaling pathways important for cell migration,
including activation of neurotrophic tyrosine kinase receptor type 1
(TrkA) and FAK signaling [97].
Relationship between cell migration and resistance to pro-apoptotic stimuli
Intracellular signaling pathways involved in the acquisition of re-
sistance to pro-apoptotic stimuli by migrating glioma cells, including
the PTEN/PI3K/Akt/mTOR and NF-kB pathways, were already an im-
portant topic more than 10 years ago [31]. These pathways are not all
constitutively activated at the same time in all cells in any one glioma.
Many inhibitors of these pathways have been developed, and numerous
clinical trials have investigated these agents alone or in conjunction
with conventional radiotherapy or chemotherapy. Several recent pub-
lications have provided an update on the state of EFGR and PI3K/Akt/
mTOR inhibitors in clinical trials for glioblastoma [98,99]. So far, tar-
geted therapy directed to central intracellular signal pathways has not
yet achieved satisfactory results in glioblastoma. A future perspective
for glioblastoma therapy may be the combined inhibition of multiple
targets and more tumor-tailored strategies.
As indicated above, potassium channels may be involved both in the
migratory processes and resistance to pro-apoptotic stimuli of glio-
blastoma cells. A volume change and decrease in intracellular K+
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concomitantly occur with the initiation of apoptosis in glioma cells
[100]. Kv1.3, expressed at the plasma membrane, is also expressed at
the inner membrane of mitochondria, where it is directly inhibited by
the proapoptotic protein BAX, resulting in cytochrome c release and
initiation of apoptosis [101]. Similar mechanisms are shared by other
K+ channels implicated in apoptosis [102]. Staudacher et al. showed
that the small molecule Kv11.1 ligand doxazosin induced concentra-
tion-dependent apoptosis of human LNT-229 and U87MG glioma cells,
accompanied by cell cycle arrest in G0/G1 [68].
In addition, compared with normal cells, several human cancers
exhibit a high mitochondrial membrane potential and low expression of
the Kv1.5 channel, which both contribute to the apoptosis resistance of
cancer cells, including glioma cells [103]. Closing K+ channels or de-
creasing their expression in cancer cells increases the intracellular K+
concentration, which in turn increases the tonic inhibition that cyto-
solic K+ exerts on caspases [102,104].
As indicated above, glioma cells can extend tumor microtubes for
brain invasion, proliferation, and interconnection of single cells to a
syncytium that is resistant to radiotherapy [78]. Recently Weil et al.
evidenced using patient-derived glioblastoma stemlike cell lines
(GBMSCs) implanted into the brain of mice that after a surgical lesion
GBMSCs increasingly extended tumor microtubes toward the lesion
area [105]. In fact, an excessive “healing response” was observed in
which tumor cell densities signiﬁcantly exceeded those of unlesioned
brain regions. Moreover, inhibition of tumor microtube formation and
function by genetic targeting of growth associated protein-43 robustly
suppressed this surgery-induced tumor growth reaction, in contrast to
standard postsurgical anti-inﬂammatory treatment with dex-
amethasone. After one cycle of TMZ chemotherapy, intra- and inter-
tumoral heterogeneity of tumor microtube formation and inter-
connection was strongly associated with therapy response: when tumor
cells were integrated in tumor microtube networks, they were more
likely to resist chemotherapy [105].
New anti-glioblastoma drugs related to migration, invasion and
resistance to apoptosis
Targeting glutamate
The multitude of eﬀects of glutamate in glioma biology has
Fig. 3. Pathways of intercellular communication in
glioblastoma. Glioblastoma demonstrates in-
tratumoral heterogeneity and contains a population
of glioma stem cells (GSC) that contributes to tumor
propagation, maintenance and therapeutic re-
sistance. After secretion, glioblastoma EV
microRNAs are taken up by other tumor cells or
normal cells in the microenvironment to change
their phenotype and support tumor progression.
Structures called microtubes connect tumor cells,
enabling these cells to act as a single, organism-like
unit. Tumor microtubes facilitate invasion into
healthy brain tissue, permitting the spread of toxic
molecules, such as Ca2+, which build up during
radiotherapy enabling the whole unit to share the
burden of toxicity. Furthermore, if tumor tissue is
surgically removed, then newly synthesized nuclei
donated by tumor cells can travel down the micro-
tube to the cell-free site to form new tumor cells.
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supported the rationale for the pharmacological targeting of glutamate
receptors and transporters in the treatment of glioblastoma ([106] for
review). Using the web site http://www.clinicaltrials.gov/ as a re-
ference, we analyzed the few clinical trials completed with therapies
targeting glutamate (see also [107]).
Glutamate release can be inhibited by sulfasalazine, an FDA-ap-
proved drug for the treatment of inﬂammatory bowel disease, through
inhibition of the CXC network. This drug may also facilitate death re-
ceptor-mediated apoptosis of glioma cells [108]. Sulfasalazine could be
considered a therapeutic agent for glioma patients to reduce seizure
activity and control invasive growth in patients, although a preliminary
study of ten patients with recurrent glioblastoma indicated lack of
clinical eﬃcacy [109] (Table 1). Yet, small series of 10 patients are
insuﬃcient to draw deﬁnitive conclusions about the potential ther-
apeutic beneﬁt of any given drug. Accordingly, Huberfeld and Vecht
have discussed the potential for single therapeutic agents, such as the
CXC system blocker sulfasalazine or histone deacetylase inhibitor val-
proic acid, to treat both gliomas and associated epilepsy [110]. How-
ever, the same year valproic acid was deﬁnitively excluded as a useful
therapeutic approach after the analysis of survival of a pooled patient
cohort (n= 1869) of four contemporary randomized clinical trials in
newly diagnosed glioblastoma patients that received the antiepileptic
drug at the start of chemoradiotherapy with temozolomide [111].
Talampanel, an allosteric inhibitor of AMPA receptors, entered
phase II clinical trials, and it has been speculated that this drug may
provide a survival advantage when used in combination with standard
chemoradiotherapy [112,113] (Table 1). However, Grossman and col-
leagues challenged their own conclusions one year later [114]. Overall
survival of 244 patients with newly diagnosed glioblastoma accrued to
three consecutive therapeutic trials conducted by the New Approaches
to Brain Tumor Therapy (NABTT) CNS Consortium was signiﬁcantly
higher than is reported with radiation and temozolomide alone [30].
The improvement in survival was evident as early as 6months after
study initiation (94% vs 86% survival, p < 0.003) and continued over
two years (37% vs 27%, p < 0.02). In each of these trials a novel agent
including talampanel for 72 patients was combined with standard ra-
diation and temozolomide [114]. This report documents signiﬁcant
improvements in the survival of patients with newly diagnosed glio-
blastoma. However, Grossman et al. emphasized that it remains un-
certain if these results are attributable to the novel therapies themselves
or reﬂect evolving patterns of care in this patient population [114]. This
argues strongly against the overinterpretation of survival data from
uncontrolled phase II studies in newly diagnosed glioblastoma, as has
recently been conﬁrmed with the negative outcome of the phase III ACT
IV trial [115].
Memantine, a noncompetitive inhibitor of NMDA receptors ap-
proved for dementia treatment, is a candidate for modulating the eﬀects
of glutamate at the inﬁltrative rim of gliomas [35,107]. Indeed, a phase
I factorial trial of temozolomide, memantine, meﬂoquine, and met-
formin for post-radiation therapy glioblastoma is ongoing (https://
clinicaltrials.gov/ct2/show/NCT01430351?term=memantine&cond=
glioma&rank=3) (Table 1).
The goal of this study is to identify the highest tolerable dose of TMZ
in combination with a mixture of memantine, meﬂoquine, and/or
metformin that can be administered to glioblastoma patients who have
previously undergone radiation and chemotherapy in combination. The
safety of these drug combinations will also be studied (https://
clinicaltrials.gov/ct2/show/NCT01430351?term=memantine&cond=
glioma&rank=3). However, whether such complex trials advance
standards of care in glioblastoma remains doubtful, and exploring the
addition of high doses of memantine alone to standard chemor-
adiotherapy might have been preferable. Yohay et al. demonstrated that
the local polymer-based delivery of riluzole, a glutamate uptake blocker
approved for the treatment of amyotrophic lateral sclerosis, or mem-
antine improved survival in a rat intracranial glioma model when the
polymer wafers were placed at the time of tumor engraftment [116].
We speculate that normal neurons might be protected against the
high glutamate microenvironment by speciﬁc inhibitors of ionotropic
receptors but further research is warranted [117,118].
Targeting ion channels
One Cl- channel inhibitor, TM-601, a synthetic version of the pep-
tide chlorotoxin, a small 36 amino acid neurotoxin isolated from the
venom of the giant yellow Israeli scorpion Leiurus quinquestriatus [119]
that is covalently linked to iodine 131, has completed phase I and II
clinical trials for the treatment of anaplastic astrocytomas and glio-
blastomas through repeated local intracavitary administrations
(NCT00591058) [46,120] (Table 1). Intracavitary-administered 131I-
TM-601 is well tolerated, remains highly localized to the treatment site,
and preliminarily appears safe for repeated injections. As no major
toxicity and no death due to 131I-TM-601 have been reported, the FDA
allowed the trial to go to Phase III [121]. An FDA approval has also
been obtained to investigate the eﬀect of TM601 in newly diagnosed
gliomas. TM601 appears to be stable, is not immunogenic and lacks
toxicity in humans upon local administration. Parallel to this trial, the
same team has worked on an intravenous injection protocol of this
product but this time with an imaging application in perspective [122].
However, to our knowledge no study has been published recently. In-
terestingly, intracranial injection of 131I-CTX detects brain tumors by
gamma-ray scintigram scans in vivo, but also labels the stomach, in-
dicating that the molecular target of chlorotoxin is also expressed in this
organ. So far, TM-601 is the only derivative of chlorotoxin for which
human clinical studies have been partially published. Besides the clin-
ical trial of 131I-TM-601, many other chlorotoxin applications have
been described that may be potentially useful to treat glioma. A large
proportion of them rely on the administration of therapeutic agents,
cDNA or siRNA to block oncogene expression, thanks to the use of
nanoparticles [123,124].
Molecular targets for chlorotoxin include voltage gated chloride
channels, calcium-dependent phospholipid-binding protein annexin-2,
and matrix metalloproteinase-2 (MMP-2) [125]. Among these targets,
MMP-2 has most anti-neoplastic potential [125].
According to Pardo and Stühmer [48] and our previous study [53],
inhibition of potassium channels also has therapeutic potential for
glioblastoma patients. Wulf et al. have previously discussed the phar-
macological strategies for targeting potassium channels with venom
peptides, antibodies or small molecules [126]. The Kv10.1 and Kv11.1
inhibitors have been proposed for the treatment of various types of
cancers. Two potent blockers of Kv10.1, the antihistamine, astemizole,
and the tricyclic antidepressant, imipramine, have been shown to de-
crease tumor cell proliferation in vitro and, in the case of astemizole,
Table 1
Potential treatment approaches in clinical study.
Targets Compounds Indications Study Ref.
Glutamate release by CXC network Sulfasalazine Recurrent glioblastoma Phase I/II [109]
AMPA receptors Talampanel Newly diagnosed glioblastoma Phase II in association with radio- and temozolomide [112–114]
NMDA receptors Memantine Glioblastoma Phase I in association with temozolomide On going
Cl-channel TM-601 Anaplastic astrocytoma and glioblastoma Phases I/II and III intracavitary [46,120]
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also in vivo [127]. Imipramine binds to the intracellular pocket and
consequently inhibits the current of Kv10.1 [128]. Desipramine and
imipramine have been demonstrated to inhibit PI3K/Akt/mTOR sig-
naling and induce autophagic cell death in vitro in murine C6 and
human U87MG glioma cells [129,130].
Recently, Sales et al. showed that in vitro suppression of the Kv10.1
channel using astemizole or silencing using a short-hairpin RNA ex-
pression vector sensitized U87MG glioma cells to temozolomide [131].
Kv11.1 is aﬀected by drugs that cause acquired long QT syndrome
[132]. Even if the intracellular channel pore openings of Kv10.1 and
Kv11.1 are similar, although not identical, all of the known Kv10.1
blockers are also eﬀective blockers of Kv11.1 and therefore share car-
diac safety problems. For these reasons, the antihistamine astemizole
was withdrawn from the market in 2000 [133]. Because the risk beneﬁt
proﬁle of an anticancer drug is radically diﬀerent from that of com-
pounds developed for the treatment of benign conditions, the potential
for these compounds should be reconsidered for repositioning. More-
over, there are at least three alternative transcripts of Kv11.1, which are
diﬀerentially expressed in heart versus tumor cells, suggesting the op-
tion of selective inhibition of this type of ion channel in tumors while
preserving heart function. A speciﬁc peptide toxin that can achieve this
result has yet to be reported. However, a monoclonal antibody (mAb56)
has been developed that speciﬁcally blocks Kv10.1 without aﬀecting
Kv11.1 or its close relative Kv10.2 [134]. This antibody showed eﬃcacy
in vitro against human melanoma MDA-MB-435S and human pancreatic
carcinoma AsPC-1 cell lines as well as in vivo in nude mice sub-
cutaneously grafted with these tumor models, but the required doses
were high, whereas the reduction of tumor growth was modest [134].
The experiments were performed in immunodeﬁcient mice, so that the
antibody could, in principle, act exclusively as a channel blocker. Fi-
nally, the anticancer compound roscovitine, a cyclin-dependent kinase
inhibitor that has terminated phase II clinical trials for non-small cell
lung cancer [135], is an eﬃcient blocker of Kv11.1, but does not induce
arrhythmia, likely due to its low aﬃnity for closed and inactivated
states of the channel.
Staudacher et al. recently identiﬁed the Kv11.1 ligand doxazosin as
a small molecule compound that promotes apoptosis and exerts anti-
proliferative eﬀects in human glioblastoma cells in vitro [68]. Doxazosin
and future derivatives have therefore been proposed as novel options
for more eﬀective glioblastoma treatment [68].
Citalopram (Cipramil®), a selective serotonin reuptake inhibitor
used for its antidepressive activity, acts on Kv1.5 currents as an open-
channel blocker [53]. Because both imipramine and citalopram have
been commonly used to treat depression, which commonly occurs in
glioma patients, the European Organization for Research and Treatment
of Cancer (EORTC) conducted a large epidemiological study to in-
vestigate the actual beneﬁt that these two drugs may provide for glio-
blastoma patients. D’Alessandro et al. demonstrated that (i) blockade of
the calcium-activated potassium channel KCa3.1 with TRAM-34, a high
aﬃnity blocker of KCa3.1, exhibits good selectivity for these channels
and increases the TMZ antitumor eﬀects, reducing GL-261 glioma cell
migration, invasion and colony forming activity, increasing apoptosis
and forcing cells to pass the G2/M cell cycle phase, likely through cdc2
de-phosphorylation; (ii) KCa3.1 silencing potentiates the inhibitory
eﬀect of TMZ on glioma cell viability; (iii) the combination of TMZ and
TRAM-34 attenuates the toxic eﬀects of glioma conditioned medium on
neuronal cultures through a microglia-dependent mechanism since the
eﬀect is abolished by clodronate-induced microglia killing; (iv) TMZ/
TRAM-34 co-treatment increases the number of apoptotic tumor cells
and the mean survival time in a syngeneic mouse glioma model
(C57BL6 mice implanted with GL261 cells); and (v) TMZ/TRAM-34 co-
treatment reduces the cell viability of glioblastoma cells and cancer
stem cells freshly isolated from patients [136]. Taken together, these
data demonstrate that TMZ/TRAM-34 co-treatment aﬀects both glioma
cells and inﬁltrating microglial cells, resulting in an overall reduction of
tumor cell progression. Furthermore, calcium activated potassium
channel blockade by paxilline, a toxin of the fungus Penicillium paxilli,
inhibited ionizing radiation-induced migration in vivo in an orthotopic
model of the human glioblastoma model [137]. Additionally, ophio-
bolin-A, a sesterterpenoid phytotoxin produced by pathogenic fungi of
the genus Bipolaris, induced marked changes in the dynamic organi-
zation of the F-actin cytoskeleton and inhibited proliferation and mi-
gration of glioblastoma cells, likely by inhibiting conductance Ca(2+)-
activated potassium channel activity [138].
Targeting extracellular miRNAs
MicroRNAs are secreted into the extracellular space, at least in part
by EV, and are subsequently taken up by normal and cancer cells to
sustain and promote tumor growth (Fig. 3). Glioblastoma EVs transport
several tumor-speciﬁc microRNAs; however, the functions of most of
these microRNAs remain unknown. A better understanding of the role
of secreted microRNAs may unveil a novel mechanism of glioblastoma
progression and resistance to current treatments and may provide novel
diagnostic and prognostic biomarkers. Rooj et al. suggested that these
biomarkers can be used for the development of targeted therapies
aimed at improving glioblastoma patient outcomes [92].
Conclusion and perspectives
Glioblastoma is an incurable neoplasm characterized by diﬀusely
inﬁltrative growth. Given the highly invasive nature of glioblastoma, it
remains unlikely that any single therapeutic approach will be able to
speciﬁcally target and eliminate residual heterogeneous tumor cells.
New therapeutic strategies to ﬁght both migrating apoptotic resistant
and proliferating glioma cells are necessary to eﬀectively counteract
glioblastoma progression. Novel treatment approaches have to in-
tegrate the intracellular perspective of the complex intracellular sig-
naling pathways with the microenvironmental orchestral machinery,
including connections between heterogeneous tumoral and nontumoral
cells, potentially also through channels, microtubes, and extracellular
miRNA, generating diﬀerent messages at diﬀerent times. New avenues
for glioblastoma treatment must not ignore the very speciﬁc and pe-
culiar interactions between tumor cells and their host tissue, and the
prime targets currently appear to be glutamate- and ion channel-con-
trolled processes.
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